Full Title
A Phase 1/2, First-in-human Study of VNX-202 Gene Therapy in Patients with HER2-Positive Cancer (SENTRY-HER2)Purpose
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Contact
For more information or to see if you can join this study, please call Dr. Nicholas Mai’s office at 646-888-4226.
Protocol
26-096
Phase
Phase I/II (phases 1 and 2 combined)
Disease Status
Newly Diagnosed
Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT07192432
ClinicalTrials.gov